Edwards Lifesciences (STU:EWL) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:EWL Edwards Lifesciences Corp STU:EWL
95 GF Score
Price €76.86
GF Value €81.87
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Edwards Lifesciences Short-term investments?

Short-term investments only applies to insurance companies.

STU:EWL
95GF Score
Edwards Lifesciences Corp STU:EWL
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Edwards Lifesciences (STU:EWL) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of €76.86 is trading 6.1% below its estimated GF Value™ of €81.87. GuruFocus considers Edwards Lifesciences to be Fairly Valued.

Key valuation signals for STU:EWL:

  • Short-term investments:
  • GF Value™: €81.87 vs. price of €76.86 (6.1% below fair value)
  • GF Score™: 95/100 with 3 warning signs

No single metric tells the full story. See the STU:EWL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Edwards Lifesciences Corp is a US-based medical device company focused on cardiovascular care, particularly structural heart disease and critical care monitoring. Spun off from Baxter International in 2000, it develops, manufactures, and markets products including surgical tissue heart valves, transcatheter aortic valve replacement systems, and transcatheter mitral and tricuspid repair and replacement technologies. Its portfolio also includes hemodynamic monitoring devices and related critical care products. The company serves hospitals, cardiac surgeons, interventional cardiologists, and intensive care clinicians worldwide. It generates revenue primarily through the sale of medical devices and disposables, supplemented by training, services, and support for its transcatheter platforms. Edwards operates globally, with a significant share of sales outside the United States, particularly in Europe and Japan, and continues to invest in clinical trials and research to expand treatment options for patients with heart valve disease and other cardiovascular conditions.
95GF Score

Get the complete analysis for STU:EWL

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€76.86
Price
€81.87
GF Value